Zhangzhou Pientzehuang Pharmaceutical (600436.CH) - Disappointing Performance Is Just the Beginning
321 Views21 Nov 2022 09:01
The investment logic of PienTzeHuang has changed, with more downside in valuation ahead. It's time to think about long logic from a broader perspective not just track performance of individual company
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- China Healthcare Weekly (Nov25)-Wuxi Biologics, Valuation Logic Changed by NRDL, Biotech Model Fails27 Nov 2022
- China Personal Pension Scheme - Standing at the Starting Point of A-Share Bull Market24 Nov 2022
- China Funeral Industry - Investment Opportunity with Both Alpha and Beta Superposition23 Nov 2022
- Zhangzhou Pientzehuang Pharmaceutical (600436.CH) - Disappointing Performance Is Just the Beginning21 Nov 2022
- China Resources Pharmaceutical (3320.HK) - Here Are the Concerns18 Nov 2022
- Xi-Biden Meeting and G20 - A Temporary Respite?16 Nov 2022
- Sinopharm Group (1099.HK) - Industry Trends Hardly Support High Valuation Expectations17 Aug 2022
x